Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Sales | 20,254 | 24,565 | 25,204 | 21,848 | 18,781 |
| Cost of Goods | 2,330 | 2,471 | 2,453 | 2,229 | 1,728 |
| Gross Profit | 17,924 | 22,094 | 22,751 | 19,619 | 17,053 |
| Operating Expenses | 55,168 | 50,223 | 40,749 | 45,687 | 43,521 |
| Operating Income | -36,914 | -27,658 | -17,545 | -25,839 | -25,740 |
| Interest Expense | 4,068 | 3,892 | 2,721 | 3,461 | 2,447 |
| Other Income | -2,469 | -3,313 | -3,316 | -4,065 | -4,045 |
| Pre-tax Income | -43,451 | -34,863 | -23,582 | -33,365 | -32,232 |
| Income Tax | 392 | 2,649 | 91 | 38 | 54 |
| Net Income Continuous | -43,843 | -37,512 | -23,673 | -33,403 | -32,286 |
| Net Income | $-43,843 | $-37,512 | $-23,673 | $-33,403 | $-32,286 |
| EPS Basic Total Ops | -0.92 | -0.76 | -0.51 | -0.82 | -0.87 |
| EPS Basic Continuous Ops | -0.92 | -0.76 | -0.51 | -0.82 | -0.87 |
| EPS Diluted Total Ops | -0.92 | -0.76 | -0.51 | -0.82 | -0.87 |
| EPS Diluted Continuous Ops | -0.92 | -0.76 | -0.51 | -0.82 | -0.87 |
| EPS Diluted Before Non-Recurring Items | -0.92 | -0.80 | -0.55 | -0.91 | N/A |
| EBITDA(a) | $-37,616 | $-28,926 | $-18,551 | $-26,067 | $-25,800 |